Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is currently being extensively employed in MPN-associated myelofibrosis therapy, but it has little antioxidative capacity. The gene discussed is JAK2; the disease is myeloproliferative disorder.